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Introduction: We previously found decreased levels of Coenzyme Q10 (CoQ10) in patients with septic shock. The
objective of the current study was to assess whether the provision of exogenous ubiquinol (the reduced form of
CoQ10) could increase plasma CoQ10 levels and improve mitochondrial function.
Methods: We performed a randomized, double-blind, pilot trial at a single, tertiary care hospital. Adults
(age ≥18 years) with severe sepsis or septic shock between November 2012 and January 2014 were included.
Patients received 200 mg enteral ubiquinol or placebo twice a day for up to seven days. Blood draws were
obtained at baseline (0 h), 12, 24, 48, and 72 h. The primary outcome of the study was change in plasma CoQ10
parameters (total CoQ10 levels, CoQ10 levels relative to cholesterol levels, and levels of oxidized and reduced
CoQ10). Secondary outcomes included assessment of: 1) vascular endothelial biomarkers, 2) inflammatory
biomarkers, 3) biomarkers related to mitochondrial injury including cytochrome c levels, and 4) clinical outcomes.
CoQ10 levels and biomarkers were compared between groups using repeated measures models.
Results: We enrolled 38 patients: 19 in the CoQ10 group and 19 in the placebo group. The mean patient age was
62 ± 16 years and 47 % were female. Baseline characteristics and CoQ10 levels were similar for both groups. There
was a significant increase in total CoQ10 levels, CoQ10 levels relative to cholesterol levels, and levels of oxidized
and reduced CoQ10 in the ubiquinol group compared to the placebo group. We found no difference between the
two groups in any of the secondary outcomes.
Conclusions: In this pilot trial we showed that plasma CoQ10 levels could be increased in patients with severe
sepsis or septic shock, with the administration of oral ubiquinol. Further research is needed to address whether
ubiquinol administration can result in improved clinical outcomes in this patient population.
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Severe sepsis and septic shock continue to be leading
causes of morbidity and mortality despite widespread
implementation of strategies focused on early antibiotic
administration and aggressive resuscitation [1]. Annually
there are an estimated 751,000 cases of severe sepsis in
the United States, with mortality upwards of 29 % [2].
Sepsis-induced multiple organ system failure is a com-
mon final pathway believed to be caused by a systemic
inflammatory response involving micro- and macro-
circulatory dysfunction and alterations in cellular metab-
olism, particularly mitochondrial dysfunction, though
the exact mechanisms remain unknown [3–5]. Recent
large trials of specific hemodynamic interventions have
failed to show a clear benefit in patients with severe sep-
sis or septic shock [6–8], and new adjunct therapies are
needed to improve outcomes.
Coenzyme Q10 (CoQ10) is a fat-soluble molecule syn-
thesized in the mitochondrial inner membrane that exists
both in oxidized form (ubiquinone) and reduced form
(ubiquinol). The mitochondrial electron transport chain
contains two transporters (CoQ10 and cytochrome c) and
four complexes (I-IV). CoQ10 plays an essential role in
the electron transport chain as the carrier of electrons
from complex I and II to complex III. Disruption of this
mechanism can compromise oxidative phosphorylation,
thereby leading to decreased levels of cellular energy (ad-
enosine triphosphate (ATP)) production [9].
Our group has previously found decreased levels of
CoQ10 in patients with septic shock [10], indicating the
possibility that cellular energy production is compro-
mised in this disease state. We also found that levels of
CoQ10 were inversely associated with levels of vascular
cell adhesion molecule 1 (VCAM-1) and the anti-
inflammatory cytokine interleukin-10 (IL-10), suggesting
that CoQ10 may also play a role in vascular endothelial
dysfunction and the inflammatory response seen in severe
sepsis and septic shock [10].
Based on these findings, we hypothesized that CoQ10
deficiency in septic patients may contribute to mitochon-
drial dysfunction, and that this dysfunction could be miti-
gated by exogenous administration of ubiquinol (reduced
CoQ10). Thus, we conducted a randomized, double-blind,
placebo-controlled, pilot trial providing enteral ubiquinol
supplementation to patients with severe sepsis or septic
shock to determine absorption and the effect of supple-
mentation on systemic levels, as well as the effect of ubi-
quinol on mitochondrial injury, markers of inflammation,
and markers of vascular endothelial injury.
Materials and methods
Design and setting
This was a single-center, randomized, double-blind, pilot
phase II trial comparing ubiquinol to placebo inpatients with severe sepsis or septic shock. The study
was conducted at Beth Israel Deaconess Medical Center
(BIDMC), which is an urban tertiary care hospital in
Boston, Massachusetts with approximately 55,000
emergency department visits annually and a total of
77 intensive care unit beds. The study was approved
by the Committee on Clinical Investigations at BIDMC
(approval number: 2012P-000267) and patients or their
legally authorized surrogate provided written informed
consent prior to enrollment. The trial was registered at
Clinicaltrials.gov (identifier: NCT01948063) and was
sponsored by Kaneka Corporation, Japan. The trial was
investigator-initiated and the sponsor was not involved in
study design or conduct, and had no role in manuscript
preparation.
Study population
The hospital’s emergency department and intensive
care units were screened for eligible patients between
November 2012 and January 2014. Inclusion criteria
were that patients were aged ≥18 years and were diag-
nosed with severe sepsis or septic shock. Severe sepsis was
defined as the presence of two or more systemic in-
flammatory response syndrome criteria, documented or
suspected infection, and evidence of sepsis-induced organ
dysfunction or tissue hypoperfusion as defined by the
Surviving Sepsis campaign [1]. Septic shock was defined
as sepsis-induced hypotension persisting despite adequate
fluid resuscitation, in accordance with the Surviving Sepsis
campaign definitions [1].
We excluded patients based on the following criteria: 1)
currently on CoQ10 supplementation, 2) unable to receive
enteral medication per the clinical team, 3) enrolled in an-
other ongoing study, 4) non-English speaking, 5) patient
unable to consent and legally authorized surrogate not
present, 6) ‘do not resuscitate’, ‘do not intubate’ or ‘comfort
measures only’ designation, or 7) member of a protected
population.
Randomization, study drug, and blinding
A master randomization list was created using SAS (SAS
Institute, Cary, NC, USA), randomizing patients to ubi-
quinol or placebo in a 1:1 ratio. The list was located in
the central pharmacy for the duration of the study. The
study drug (placebo or ubiquinol) was administered as a
pill by mouth or in liquid form per nasogastric tube if
present. Given the distinct taste of the liquid, this was
not provided to all patients. The study drug was admin-
istered twice per day after enrollment, and was contin-
ued daily for seven days or until hospital discharge,
whichever came first. Ubiquinol (Kaneka Corporation,
Japan) was administered at a dosage of 200 mg per dose.
Ubiquinol was chosen over ubiquinone (oxidized
CoQ10) due to its higher bioavailability [11]. The dose
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300 mg are well-tolerated in healthy volunteers [11], and
the dose was comparable to that used in a previous
post-cardiac arrest trial [12]. The placebo was in identi-
cal pills or liquids as the study drug and patients, health-
care personnel, and the research team remained blinded
throughout the study period.
Blood samples and data collection
Venous blood was collected at enrollment immediately
before administration of study drug (0 h) and at 12, 24,
48, and 72 h thereafter. Samples were centrifuged and
serum and plasma were aliquoted into light-protected
cryotubes and immediately frozen at −80 °C.
Upon enrollment, we recorded demographic data, co-
morbid conditions, vital signs, clinical laboratory values,
whether or not the patient was receiving mechanical
ventilation or vasopressors, and calculated the Acute
Physiology and Chronic Health Evaluation II (APACHE
II) score. Vital signs and laboratory values were also col-
lected at all subsequent time points and outcome data,
including length of intensive care unit stay, length of
hospital stay, and mortality, was collected at patient dis-
charge. All data was entered into a secure, online data-
base by trained research assistants.
Outcome measures
The primary outcome of the study was change in plasma
CoQ10 parameters (total CoQ10 levels, CoQ10 levels
relative to cholesterol levels, levels of oxidized (ubiquin-
one) and reduced (ubiquinol) CoQ10, and the fraction of
reduced CoQ10 (reduced CoQ10/total CoQ10 levels)).
Secondary outcomes included were: 1) assessment of
vascular endothelial function via vascular endothelial
growth factor (VEGF) and VCAM-1 measurements, 2)
assessment of inflammation via IL-2, IL-6, IL-10, and
tumor necrosis factor (TNF)-α measurements, 3) assess-
ment of mitochondrial injury via cytochrome c levels
and DNA markers, and 4) assessment of clinical out-
comes (length of ICU and hospital stay, and in-hospital
mortality).
Measurement of Coenzyme Q10 levels and biomarkers
CoQ10 levels were measured in plasma samples by the
Department of Pathology and Laboratory Medicine at
Cincinnati Children’s Hospital Medical Center (Cincin-
nati, Ohio, USA) using high-performance liquid chroma-
tography as previously described in detail [13]. We
measured three different CoQ10 parameters (total
CoQ10, oxidized CoQ10, and reduced CoQ10 (all mea-
sured in μg/mL)), as well as total cholesterol levels.
From these, two additional parameters were calculated:
total CoQ10/cholesterol and reduced CoQ10/totalCoQ10. CoQ10 levels were measured at the 0, 12, and
24 h time points.
Plasma samples were analyzed for multiple vascular
endothelial and inflammatory markers (VEGF, VCAM-1,
IL-2, IL-6, IL-10, and TNF-α) using customized Meso
Scale Discovery Human Multiplex Panel (Rockville,
Maryland, USA). All samples were measured in duplicate
with the inter-assay coefficients of variability ranging from
2.2 to 5.8 %. VCAM-1 is reported in log-transformed
μg/mL and the rest of the markers in log-transformed
pg/mL. Cytokine levels were measured at the 0, 12, 24, 48
and 72 h time points.
Cytochrome c levels were measured by electroche-
miluminescence in a Quickplex SQ 120 instrument
(Meso Scale Discovery) at the Resuscitation Institute/
Rosalind Franklin University of Medicine and Science
(North Chicago, IL, USA). Cytochrome c levels had
previously been reported to correlate inversely with
survival after cardiac arrest in rodents [14]. Standard
curves were prepared using commercially available human
heart cytochrome c (cat# C3483-10UG, Sigma-Aldrich, St.
Louis, MO, USA) diluted in 10 % pooled human plasma
from healthy volunteers in assay buffer at concentrations
of 1,200.0 ng/mL, 400.0 ng/mL, 133.3 ng/mL, 44.4 ng/mL,
14.8 ng/mL, 4.9 ng/mL, 1.6 ng/mL, and 0 ng/mL. Each
plasma sample with an unknown cytochrome c concentra-
tion was thawed in ice and diluted 1:1 in the assay buffer.
Samples and standards (in a volume of 25 μL) were run in
duplicate. Data analysis was performed using Meso Scale
Discovery software, which developed the standard curve
used to calculate the unknown concentrations. The upper
limit of detection was 1,200 ng/mL and the lower limit of
detection was 4 ng/mL, which is defined as 2.5 standard
deviations above the background mean. The software also
calculates the coefficient of variation between the replicate
samples. If the sample cytochrome c concentration fell
above or below the dynamic range of the standard
curve, the assay was repeated after appropriate dilution.
Cytochrome c levels were expressed in log-transformed
ng/mL. Cytochrome c levels were measured at the 0, 12,
and 24 h time points. Cytochrome c was included as an
exploratory outcome as a potential marker of mitochon-
drial injury [14].
We measured cell-free DNA, two markers of nuclear
DNA, and two markers of mitochondrial DNA (mtDNA)
at the 0, 12, and 24 h time points. In order to measure
cell-free DNA in plasma, the plasma samples were cen-
trifuged at 16,000 g for 10 min to remove any residual
cells. The upper portion of the plasma was removed into
a nuclease-free tube and stored at −80 °C prior to DNA
extraction. Cell-free DNA in the plasma was isolated
using a plasma/serum DNA isolation kit (Abcam,
Cambridge, MA, USA) according to the manufacturer’s
protocol. The amount of cell-free DNA was measured
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Fisher Scientific, Wilmington, DE, USA). The quality of
DNA was checked by the A260/280 ratio. The amount
of mtDNA was measured with mtDNA-tRNAleu and
mtDNA-D loop genes, which are specifically present in
the mitochondrial genome. Nuclear DNA was amplified
using the single-copy beta-2-microglobulin (B2M) and
RNase P nuclear genes. Primers and probes for real-
time PCR were purchased from Life Technologies
Corporation and utilized as previously described by
Bai and Wong [15]. TaqMan real-time quantitative
PCR assay was performed on a 7500 real time PCR
system following the manufacturer’s protocol (Applied
Biosystems, Life Technologies Corporation, CA, USA).
DNA extracted from whole blood with a two-fold ser-
ial dilution was used to construct the calibrationFig. 1 Consolidated Standards for Reporting Trials (CONSORT) diagram. A t
38 were analyzed. CMO: Comfort measures only, DNI: Do Not Intubate, DNcurve. All samples were measured in duplicate with
the inter-assay coefficients of variability ranging from
1.6 to 5.5 %. Cell-free DNA was measured as a marker
of cellular injury, as well as a surrogate for poor out-
come [16–18].
Statistical analyses
Descriptive statistics were used to summarize the study
population. Data for continuous variables are presented
as means with standard deviations (SD) or medians with
quartiles, depending on the normality of the data. Cat-
egorical data are presented as counts with frequencies.
Depending on the distribution of the data, t-tests or
Wilcoxon rank sum tests were used to compare continuous
data between the groups. Categorical data were compared
using chi-squared or Fisher’s exact tests as appropriate.otal of 546 patients were screened. Of these 41 were randomized and
R: Do Not Resuscitate NPO: nil per os
Table 1 Selected baseline characteristicsa
Characteristic Ubiquinol (n = 19) Placebo (n = 19)
Demographics
Age (years) 60 ± 18 64 ± 14
Sex (female) 11 (58 %) 7 (37 %)
Race (white) 14 (78 %) 15 (83 %)
Co-morbidities
Coronary artery disease 2 (11 %) 2 (11 %)
Congestive heart failure 2 (11 %) 2 (11 %)
Hyperlipidemia 6 (32 %) 2 (11 %)
Hypertension 12 (63 %) 9 (47 %)
Chronic obstructive pulmonary disease 2 (11 %) 3 (16 %)
Diabetes 6 (32 %) 8 (42 %)
Liver disease 1 (6 %) 0 (0)
Renal disease 3 (16 %) 1 (6 %)
Cancer 4 (21 %) 9 (47 %)
Vital signs at enrollment
Heart rate 92 ± 19 88 ± 22
Systolic blood pressure 109 ± 19 105 ± 11
Diastolic blood pressure 54 ± 16 61 ± 11
Respiratory rate 25 ± 6 22 ± 6
Temperature 98.4 ± 1.4 98.7 ± 1.1
Laboratory values at enrollment
Lactate (mmol/L) 1.6 (1.1-2.5) 1.3 (1.0-1.6)
Creatinine (mg/dL) 1.7 (1.0-3.0) 1.0 (0.7-1.7)
Bicarbonate (mEq/L) 30 ± 7 34 ± 7
White blood count (K/μL) 13.2 ± 6.3 16.5 ± 11.4
Hematocrit (%) 30.0 ± 7.0 33.7 ± 7.4
Source of sepsis
Pneumonia 9 (47) 7 (37)
Urinary tract 2 (11) 2 (11)
Intraabdominal 1 (5) 3 (16)
Skin, joint, or soft tissue 2 (11) 4 (21)
Endocarditis 1 (5) 0 (0)
Unclear 4 (21) 3 (16)
Positive blood culture 5 (26) 6 (32)
Mechanical Ventilation 11 (58 %) 7 (37 %)
Vasopressors 12 (63 %) 12 (63 %)
APACHE II score at enrollment 19 ± 9 18 ± 10
Baseline CoQ10 Levels
Total CoQ10 (mcg/mL) 0.37 (0.30-0.62) 0.33 (0.25-0.69)
CoQ10 Reduced (mcg/mL) 0.31 (0.20-0.40) 0.30 (0.22-0.66)
CoQ10 Oxidized (mcg/mL) 0.05 (0.02-0.15) 0.03 (0.02-0.04)
CoQ10 %Reduced 0.87 (0.73-0.94) 0.92 (0.90-0.95)
CoQ10: Cholesterol 0.38 (0.28-0.65) 0.36 (0.26-0.55)
aBaseline values with continuous values expressed as means ± standard deviation or median (quartiles), depending on normality of the data. Categorical values
are counts with frequencies. No comparisons had a P value <0.05
Donnino et al. Critical Care  (2015) 19:275 Page 5 of 11
Donnino et al. Critical Care  (2015) 19:275 Page 6 of 11To assess the difference in repeated continuous variables
(CoQ10 levels, vascular and inflammatory biomarkers,
cytochrome c levels, and DNA markers) between groups
we used repeated measures models to account for within-
subject correlation. Variables were log-transformed before
statistical analysis. An appropriate covariance structure was
chosen and the residuals were visually assessed for normal-
ity. Due to the exploratory nature of the current study we
did not account for multiple comparisons. Statistical ana-
lyses were conducted with the use of SAS software, version
9.3 (SAS Institute Inc., Cary, NC, USA). All hypothesis tests
were two-sided, with a significance level of P <0.05.Fig. 2 CoQ10 parameters over time. Values are reported as medians with e
global tests that values are similar between groups at the 12 and 24 h timeResults
Study population
A total of 546 patients with severe sepsis or septic shock
were screened and 41 patients were randomized. Of
those, three were excluded post-randomization (two in
the ubiquinol group and one in the placebo group), leav-
ing 38 for the final analysis (see Fig. 1). The median age
was 62 ± 16 years and 47 % were female. The overall
mortality was 16 %. There were no statistically signifi-
cant differences between the baseline characteristics for
the ubiquinol group and the placebo group, as illustrated
in Table 1.rrors bars indicating first and third quartiles. The P values represent the
points
Fig. 3 Vascular and inflammatory biomarkers over time. Values are reported as log-transformed means with errors bars indicating standard deviations.
The P values represent the global tests that values are similar between groups at the 12, 24, 48, and 72 h time points
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The baseline CoQ10 levels in the two groups were simi-
lar. At 12 and 24 h after study drug administration there
were increased levels of total CoQ10 (P <0.001), CoQ10
levels relative to cholesterol levels (P <0.001), reduced
CoQ10 levels (P = 0.006) and oxidized CoQ10 levels
(P = 0.002) in the ubiquinol-treated group compared
to the placebo group. There was no statistically sig-
nificant difference in the fraction of reduced CoQ10
(P = 0.15) (Fig. 2).
Vascular endothelial and inflammatory markers
There was no difference in baseline vascular endothe-
lial and inflammatory markers between the groups.IL-6 levels at 12, 24, 48, and 72 h were higher in
patients receiving ubiquinol as compared to those
receiving placebo (P = 0.02). There was no difference
between the ubiquinol and placebo groups in levels
of VEGF (P = 0.41), VCAM-1 (P = 0.05), TNF-α
(P = 0.23), IL-2 (P = 0.88), or IL-10 (P = 0.45) over
time (Fig. 3).Cytochrome c
There was no difference in baseline cytochrome c levels
between groups. At 12 and 24 h after study drug admin-
istration, there was also no difference in cytochrome c
levels between groups (P = 0.32, Fig. 4).
Fig. 4 Cytochrome c values over time. Values are reported as
log-transformed means with errors bars indicating standard deviations.
The P values represent the global tests that values are similar between
groups at the 12 and 24 h time points
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There was no difference in baseline cell-free DNA, B2M,
RNase P, mtDNA-D loop, or mtDNA-RNAleu between
the groups. There was no difference in cell-free DNA
between the two groups (P = 0.95). There was no dif-
ference in the fold change of B2M (P = 0.76), RNase
P (P = 0.87), mtDNA-D loop (P = 0.58), or mtDNA-
RNAleu (P = 0.71) over time (Fig. 5).
Clinical outcomes
There was no difference in ICU length of stay (5 (3 to 7)
versus 3 (2 to 6) days, P = 0.30) or hospital length of stay
(11 (6 to 19) days versus 10 (6 to 19) days, P = 0.82)
between the two groups. These results were similar
when only analyzing survivors. There was no difference
in in-hospital mortality between patients receiving ubiqui-
nol versus placebo (4 (21 %) versus 2 (11 %), P = 0.66).
The four deaths in the ubiquinol group happened 1, 1, 5,
and 16 days after the drug administration. The mode of
death was determined to be comorbid withdrawal of care
in two patients with underlying terminal illness, refractory
hypotension in one patient with underlying terminal ill-
ness, and progressive respiratory failure in one patient
with underlying alcohol-associated hepatic failure. The
mode of death for the two patients in the placebo group
was determined as comorbid withdrawal of care in one
patient with terminal illness, and refractory hypotension
in one patient with underlying terminal illness (both
deaths occurred four days after drug administration). As
noted, the majority of deaths occurred in patients with a
preexisting terminal illness, including metastatic cancer or
end-stage organ failure. None of the deaths were deter-
mined to be related to the study medication as assessed byan independent data safety monitoring board. Gastrointes-
tinal disturbance, potentially related to ubiquinol adminis-
tration, was reported in one patient.
Discussion
In this pilot study of ubiquinol versus placebo in patients
with severe sepsis and septic shock, plasma CoQ10
levels increased in patients who received ubiquinol. We
found statistically significant higher levels of IL-6 in pa-
tients receiving ubiquinol as compared to those receiv-
ing placebo. The reason for this finding remains largely
unexplained, but could be related to multiple testing.
The assessment of other biomarkers related to vascular
endothelial function, mitochondrial dysfunction, and in-
flammation revealed no statistically significant differ-
ence between the ubiquinol and the placebo groups
in this study.
CoQ10, as a key component of the electron transport
chain, plays an important role in the mitigation of oxida-
tive stress and production of cellular energy [19]. Previ-
ous investigations have demonstrated that CoQ10 levels
are low in critical illness, specifically septic shock and
post-cardiac arrest [10, 20, 21]. Multiple rat models have
been used to test and demonstrate the beneficial impact
of CoQ10 in sepsis and have found decreased oxidative
stress, prevention of mitochondrial damage, less renal
and acute liver dysfunction, and neuroprotective effects
[22–24]. In the current study, we demonstrate that ex-
ogenous provision of ubiquinol increases CoQ10 levels
in patients with severe sepsis and septic shock. The po-
tential benefits of this increase remain unclear.
Severe sepsis is associated with respiratory, cardiovas-
cular, and renal dysfunction, with significant alterations
to metabolic pathways and cellular function [25, 26]. A
central hypothesis in organ dysfunction is the concept of
tissue hypoxia [27]. Cytopathic hypoxia (compromised
cellular oxygen utilization), rather than inadequate oxy-
gen delivery, may play a significant role in the develop-
ment of multi-organ dysfunction and lactate elevation in
sepsis [28, 29], although the exact mechanisms remain
unknown [30]. Despite optimization of hemodynamics
and oxygen therapy, oxygen may not be utilized at the
mitochondrial level. Mitochondria consume 90 % of cel-
lular oxygen in order to generate energy as ATP, via oxi-
dative phosphorylation by transfer of electrons from the
Krebs cycle to the electron transport chain, via nicotina-
mide adenine dinucleotide and 5,10-methylenetetrahy-
drofolate reductase [31]. The electron transport chain is
located on the inner mitochondrial membrane and con-
sists of four complexes and two transporters. CoQ10
plays an essential role in the electron transport chain
as the carrier of electrons from complex I and II to
complex III. Disruption of this mechanism can com-
promise oxidative phosphorylation in the mitochondria,
Fig. 5 Cell-free DNA, and nucleus and mitochondrial DNA values over time. Values are reported as log-transformed means with errors bars indicating
standard deviations. The P values represent the global tests with values that are similar between groups at the 12 and 24 h time points
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duction [9].
Previous studies have demonstrated a beneficial role of
CoQ10 as a co-adjutant in the treatment of syndromes
characterized by impaired mitochondrial bioenergetics
and increased oxidative stress [32]. CoQ10 has shown
beneficial effects on diastolic and systolic function in
patients with chronic heart failure [33–35] and, in a
single-center pilot trial, CoQ10 was found to increase
three-month survival when given to post-cardiac arrest
patients [12]. Moreover CoQ10 has shown promising
clinical benefits in small human studies of progressive
supranuclear palsy [36], Huntington’s disease [37],
and Friedreich’s ataxia [38]. Finally, CoQ10 has also
been studied in Parkinson’s disease, with inconsistent
results [39–41].In the current study we were unable to detect any dif-
ferences in secondary endpoints between the groups.
There are multiple possible explanations for this lack of
effect. Our sample size was relatively small, and we may
have been underpowered to detect clinically relevant
differences in biomarkers or clinical outcomes. A rela-
tively large portion of potentially eligible patients were
excluded, which may decrease the generalizability of our
findings. Given the lack of human trials in septic pa-
tients, we used a relatively low dose (200 mg twice per
day). Previous studies have demonstrated that oral con-
sumption of CoQ10 at dosages of 400, 600, 800, and
1,200 mg per day are well tolerated in patients with
Parkinson’s disease, with the greatest benefit in the
group receiving the highest dosage (1,200 mg per day)
[40, 39]. As such, our dose may have been inadequate to
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may be required to compensate for the severity of meta-
bolic dysfunction and energy depletion that occurs in
severe sepsis and septic shock.
The timing and duration of our intervention may have
influenced the results. Approximately half of our pa-
tients were mechanically ventilated and comatose at the
time of enrollment, which led to some delay in the
administration of the first dose as consent had to be
obtained from a legally authorized surrogate. The dur-
ation of therapy was relatively short (maximum of seven
days), and a longer duration and follow-up period may
be needed, especially for long-term patient-centered out-
comes. For example, ubiquinol could theoretically pro-
tect against cognitive dysfunction or muscular weakness
post-septic shock, but we did not measure these longer-
term outcomes. Further, the majority of our biomarker
endpoints were only assessed within the first 24 h. It is
possible that changes could have been seen if the end-
points were evaluated at later time points. The enrolled
patient population was heterogeneous, with a relatively
low overall mortality (16 %) that, based on review by a
blinded physician, was mainly related to withdrawal of
care in patients with underlying terminal illness. Future
studies might consider excluding patients with terminal
illness. Whether certain subgroups, such as a more
acutely ill population with potential signs of mitochon-
drial injury (for example, elevated lactate), may benefit
remains unknown. Lastly, the possibility remains that
ubiquinol is ineffective as a ‘metabolic resuscitator’ in
patients with severe sepsis and septic shock. However,
additional studies are needed before any firm conclu-
sions can be made.
Conclusions
We have shown that ubiquinol is absorbed in patients
with severe sepsis and septic shock. There were no
significant changes in VEGF, VCAM-1, the majority of
inflammatory markers, or clinical outcomes, such as
mortality and length of ICU and hospital stay. Further
investigation with different dosages, timing of drug
delivery, or more specific populations may be warranted
to determine whether ubiquinol administration may be
beneficial as an adjunct therapy in patients with severe
sepsis and septic shock.
Key messages
 Coenzyme Q10 is an essential component of the
mitochondrial electron transport chain.
 In this placebo-controlled, randomized, pilot
trial we found that enteral administration of
ubiquinol (reduced coenzyme Q10) increases total
Coenzyme Q10 levels, Coenzyme Q10 levels relativeto cholesterol levels, and levels of oxidized and
reduced Coenzyme Q10.
 There was no difference in vascular endothelial
biomarkers, inflammatory biomarkers, or biomarkers
related to mitochondrial injury, including
cytochrome c levels.
 We found no difference in clinical outcomes
between the ubiquinol and placebo groups.
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